Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

Article Oncology

Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events

Jaume Mora et al.

Summary: This article reviews the safety profile and adverse event management of naxitamab in a pediatric population, providing protocol-based recommendations for AE management and emphasizing the importance of close monitoring and timely intervention to ensure maximum clinical benefit from naxitamab therapy.

CANCER REPORTS (2023)

添加到收藏夹

Review Oncology

Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation

Susanne H. C. Baumeister et al.

Summary: Immune effector cells have the potential to control and eradicate malignant diseases; however, they can also cause systemic multi-organ toxicities. This review focuses on immune-related toxicities in pediatric immunotherapies and haploidentical T cell replete Hematopoietic Cell Transplantation, discussing the signs, symptoms, grading, pathophysiology, and management principles, particularly in the context of pediatric critical care.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain

A. Castaneda et al.

Summary: This article provides a practical overview of the experience with naxitamab in treating neuroblastoma at Sant Joan de Deu Children's Hospital in Barcelona. The team has used two primary regimens: naxitamab with GM-CSF only, or naxitamab in combination with irinotecan, temozolomide, and GM-CSF. Adverse event management, including the use of ketamine to manage pain during anti-GD2 mAb infusions, is also discussed.

ESMO OPEN (2022)

添加到收藏夹

Meeting Abstract Oncology

Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial

J. Mora et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Pediatrics

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

Giuseppe Barone et al.

Summary: Neuroblastoma is the most common extracranial solid tumor in children, and high-risk neuroblastoma is challenging to treat with poor prognosis. Immunotherapy with anti-GD2 antibodies, such as dinutuximab beta, has been shown to improve survival rates. However, it is associated with adverse events that may be challenging for clinicians to manage.

PEDIATRIC DRUGS (2021)

添加到收藏夹

Meeting Abstract Oncology